Moreover, we synthesized the specific enzymatic inhibitor of ZDHHC2‐TTZ1,[26] and showed that TTZ1 restores ACSL4 levels, reinstates ferroptosis sensitivity, and overcomes enzalutamide resistance in prostate cancer. Here, ZDHHC2 is linked to prostate cancer.